ArticleFrontiers in endocrinology2026
Therapeutic adherence and associated factors among high-risk patients with type 2 diabetes in primary healthcare: a cross-sectional study using real-world data from the Madrid Region.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Therapeutic adherence is a key component of chronic disease management, particularly in high-risk patients. Type 2 diabetes (T2DM) is common in this population; however, real-world evidence on therapeutic adherence and the factors associated with it among high-risk patients with T2DM remains limited in Spain and other regions. Objective: To evaluate therapeutic adherence and identify factors associated with nonadherence among high-risk patients with T2DM using real-world primary care data. Materials and methods: A cross-sectional study was conducted among adults with T2DM classified as high-risk chronic patients using primary healthcare electronic health records from the Madrid Region as of 30 April 2021. Sociodemographic, functional, clinical, lifestyle, pharmacological, and primary healthcare utilization variables were analyzed according to therapeutic adherence status. Multivariable logistic regression was performed to identify factors independently associated with therapeutic nonadherence. Results: Among 67,746 high-risk patients with T2DM, adherence information was available for 65,856 patients, of whom 45,669 (69.3%) were classified as nonadherent. Nonadherent patients had a higher prevalence of polypharmacy (62.1% vs. 58.7%) and greater healthcare utilization, with a higher mean number of primary care contacts during the first year (25.3 vs. 24.4). In the multivariable analysis, the independent factors associated with higher odds of nonadherence were older age (odds ratio (OR = 1.008), male sex (OR = 1.073), foreign status (OR = 1.157), Individual Health Card category 3 (annual income up to €18,000) (OR = 1.245), ischaemic heart disease (OR = 1.137), heart failure (OR = 1.072), COPD (OR = 1.571), asthma (OR = 1.622), depression (OR = 1.054), palliative care (OR = 1.352), smoking status (OR = 1.102), polypharmacy (OR = 1.345), and ≥20 primary care contacts (OR = 1.066). Conclusions: Therapeutic nonadherence is highly prevalent among high-risk patients with T2DM managed in routine primary care. Nonadherence was independently associated with treatment burden, specific patterns of clinical complexity, behavioral factors, and healthcare needs, with some associations showing modest effect sizes, highlighting the multifactorial nature of therapeutic adherence in this population. These findings support the integration of routine adherence assessment and individualized medication management strategies into primary care for patients with complex chronic conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.